drugset / Trial / NCT03597022
Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study was to assess the safety and tolerability of multiple doses of a human monoclonal antibody (BAY1093884) given under the skin in subjects with hemophilia A or B. This antibody was intended to protect from bleeds by inhibiting a substance (Tissue Factor Pathway Inhibitor, TFPI) that reduces the ability of the body to form blood clots.
Timeline
- Start
- 2018-07-24
- Primary completion
- 2019-10-15
- Completion
- 2019-10-15
Outcome
Outcome not reported
Stopped: “Due to thrombosis”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY1093884 | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | BAY1093884 | Monoclonal antibody | 225 mg | Subcutaneous |
| Subject | BAY1093884 | Monoclonal antibody | 400 mg | Subcutaneous |